iKang Healthcare Group, Inc. (“iKang” or the “Company”)
(Nasdaq:KANG), a major provider in China’s fast-growing private
preventive healthcare services market, has announced the launch of
its key strategic initiatives, iKangCare+ and iKangPartners+ so
that customer experience will be significantly improved. Mr. Lee
Ligang Zhang, Chairman and Chief Executive Officer of iKang,
commented, “The launch reflects iKang’s recognition of the
challenges that the industry is facing and customers’ expectation
for innovation. We have defined our strategies and are now
upgrading our product and service which will meet and exceed
client’s expectation, especially the corporate clients which make
up the majority of our revenue. Through innovative products and
service upgrade, as well big data analysis and artificial
intelligence, we are now creating a comprehensive and fully
integrated “advisory” healthcare management platform, designed to
further contribute to greater national well-being.” iKang Group has
launched iKangCare+ as a platform for corporate customers, designed
for continuous upgrade and enhancement. iKang plans to embrace
artificial intelligence and targeted services to communicate
effectively with corporate clients and deliver robust expert
healthcare management solutions. With iKangCare+, C represents
“Connecting” (connecting customers), A for “Ai” (artificial
intelligence), R for “Reliable” (more reliable service and
product), E for “Expert” (expert service as a whole), and + for
“integrated service platform.” iKang has identified an urgent
customer demand for a comprehensible explanation and
understanding of the test results of medical examination services
received from iKang, as well as adequate follow-up services for
further tests and even treatment afterwards. To facilitate direct
connection with clients to address this need, iKangCare+ corporate
clients' platform provides customers with the iKang APP, official
WeChat, medical centers and clinics, toll-free help lines, and
on-site services for a professional and full interpretation and
guidance on the results of their tests. Furthermore, based on
big data analysis and the latest technologies through advanced
imaging tools and lipid biopsy in early stage cancer screen,
iKangCare+ corporate client platform is able to generate
self-served personalized medical examination service checkup menus
for each employee based on his/her own family history, personal
heath record and lifestyles. In the past, for those companies
in China where annual medical examination services are provided as
a benefit for corporate employees, one-size-fits-all checkup menus
for all employees has been the standard practice for many years.
After the annual medical examination, the iKang
APP will identify any abnormal findings and provides a targeted
in-depth test program. This outreach tracking system will be
continuously upgraded, to fully deliver the commitment of
“advisory” support.
iKang has combined the most advanced screening
measures available and upgraded solutions related to high-morbidity
cancer into its core medical examination package – iKang’s “Three
anti-cancer precautionary package.” Focusing on early screening for
gastric cancer and colon cancer, iKang “Stomach Check Package”
introduces China’s first genotyping of helicobacter pylori in feces
and analysis of fecal DNA in early screening of colorectal cancer.
For the No.1 cancer in China – lung cancer – iKang’s “Lung Check
Package” includes liquid biopsy for ultra-early lung cancer, lung
CT scanning, and related genetic testing and cancer marker
screening programs. For more comprehensive early stage cancer
screening and disease risk assessments, iKang’s “Complete Check
Package” includes 197 test programs for male customers and 202 for
females of DNA tests, 18 types of high-morbidity cancer liquid
biopsies and lung CT scanning, etc. iKang is continuously building
its competitive advantage to reinforce contact between clients and
medical experts and addressing shortfalls in post-cancer diagnosis
via the iKangCare+ corporate client platform. iKang provides
specialist referral for clients when abnormal symptoms linked to
cancers are found in our medical centers. If the result of cancer
is confirmed, iKang offers second opinions to patients from leading
experts out of patients’ choice from any hospital in China at
iKang’s expense.
iKang and haodf.com will form a strategic
alliance that allows iKang clients to reach out to more than
150,000 recognized medical experts across the country through the
haodf.com platform. haodf.com is one of the most recognized high
quality health consultation platforms in China with anchor
investors such as Tencent and Baidu.com. Through WorldCare, a
leader in the second opinions industry which provides access to
teams of specialists who can provide independent medical
second opinions to ensure the diagnosis is accurate and recommend
an optimal treatment plan, iKang is now able to connect with over
18,000 specialists with WorldCare Consortium, including
Massachusetts General Hospital, Brigham and Women's Hospital,
Dana-Farber Cancer Institute, Boston Children's Hospital, Mayo
Clinic and UCLA Health, etc. Furthermore, through daoyitong.com
developed by iKang, the iKang platform helps patients to make
appointments with specialists in closed to 400 tertiary hospitals
in China.
In 2016, 212 of the Fortune Global 500 companies
in China and 89 of China’s top 100 companies in Forbes chose iKang
as their healthcare management provider. iKang was first among its
peers to develop the concept of “taking care of your health beyond
annual medical exams,” not only because of its commitment from its
foundation to be responsible for its customers’ health, but also
thanks to its professional ability as the industry leader, and its
partners’ support.
At the launch of the iKangPartners+ plan, Mr.
Lee Ligang Zhang stressed iKang’s commitment for “quality-first”
operational philosophy through its strong partnerships with
academic institutions and medical associations, leading providers
in the field of in vitro diagnosis and genetic testing, and world
class vendors in medical equipment such as GE, Siemens, Philips,
Roche, etc.
The concept of “taking care of your health
beyond annual medical exams” shows that the new strategic
initiative of iKang Group is not only an upgrade of products and
services, but also exploration and innovation in healthcare
management. Through the new launch of iKangCare+ and iKangPartners+
as a truly “advisory” healthcare platform, iKang is committed to
redefine the healthcare management sector with all its
participating partners in China.
About iKang Healthcare Group,
Inc.iKang Healthcare Group, Inc. is one of the largest
providers in China’s fast-growing private preventive healthcare
space through its nationwide healthcare services network.
iKang’s nationwide integrated network of
multi-brand self-owned medical centers and third-party facilities
provides comprehensive and high-quality preventive healthcare
solutions across China, including medical examination, disease
screening, outpatient service and other value-added services.
iKang’s customer base primarily comprises corporate clients, who
contract with iKang to deliver medical examination services to
their employees and clients, and receive these services at
pre-agreed rates. iKang also directly markets its services to
individual customers. In the fiscal year ended March 31, 2017,
iKang served a total of 5.58 million customer visits under both
corporate and individual programs.
As of June 26, 2017, iKang has a nationwide
network of 108(1) self-owned medical centers, covering 33 of
China’s most affluent cities: Beijing, Shanghai, Guangzhou,
Shenzhen, Chongqing, Tianjin, Nanjing, Suzhou, Hangzhou, Chengdu,
Fuzhou, Changchun, Jiangyin, Changzhou, Wuhan, Changsha, Yantai,
Yinchuan, Weihai, Weifang, Shenyang, Xi’an, Wuhu, Guiyang, Ningbo,
Foshan, Jinan, Bijie, Qingdao, Wuxi, Kaili and Mianyang, as well as
Hong Kong. iKang has also extended its coverage to over 150 cities
by contracting with approximately 400 third-party facilities, which
including select independent medical examination centers and
hospitals across all of China’s provinces, creating a nationwide
network that allows iKang to serve its customers in markets where
it does not operate its own medical centers.
(1) Among the 108 self-owned medical centers,
two medical centers are currently operated primarily by the
minority shareholders of these medical centers or their parent
company.
IR Contact:
iKang Healthcare Group, Inc.
Christy Xie
Director of Investor Relations
Tel: +86 10 5320 8599
Email: ir@ikang.com
Website: www.ikanggroup.com
FleishmanHillard
Email: ikang@fleishman.com
IKANG HEALTHCARE GROUP, INC. (NASDAQ:KANG)
Historical Stock Chart
From Mar 2024 to Apr 2024
IKANG HEALTHCARE GROUP, INC. (NASDAQ:KANG)
Historical Stock Chart
From Apr 2023 to Apr 2024